Assessment of atherothrombosis and its treatment in Mexico: First-year data of the REACH registry
Article
-
- Overview
-
- Research
-
- Identity
-
- Additional Document Info
-
- View All
-
Overview
abstract
-
Background: Atherothrombosis, a generalized and progressive process, is currently a major healthcare problem in Mexico. Methods: The worldwide Reduction of Atherothrombosis for Continued Health (REACH) registry aimed to evaluate risk factors for atherosclerosis, long-term cardiovascular (CV) event rates, and current management of either patients with established symptomatic atherosclerotic disease or asymptomatic subjects with multiple risk factors for atherothrombotic disease. One-year follow-up of the global REACH database was available for 64 977 outpatients. This report includes the Mexican subregistry wherein 62 internists, cardiologists, and neurologists evaluated baseline patient characteristics, risk factors, medications, and CV event rates as primary outcomes at 1-year follow-up. Results: Complete 1-year follow-up data were available for 837 Mexicans. We observed a high prevalence of diabetes (47.1%25), hypertension (74.7%25), and hypercholesterolemia (57.8%25). Antiplatelet, antihypertensive and/or glucose-lowering agents, and lipid-lowering drugs were used in 87.6%25, 84.1%25, and 61%25 of patients, respectively. The all-cause mortality rate was 3.3%25. The composite outcome CV death/myocardial infarction/stroke/ hospitalization for atherothrombotic events was higher in the symptomatic group (14.6%25) than in asymptomatic subjects with multiple risk factors (5.1%25; P = 0.01), similar to Latin American results of the global REACH report. The highest CV event rate occurred among symptomatic atherothrombotic patients with 3 vascular disease locations (30.2%25), followed by those with 2 (21.9%25) and 1 location (13.4%25; P = 0.0006). Conclusions: Prevalence of risk factors and CV event rates including hospitalization in Mexican atherothrombotic patients was high despite the current medication use, which suggests it is necessary to havemore aggressive risk-factor management. © 2010Wiley Periodicals, Inc.
publication date
published in
Research
keywords
-
2,4 thiazolidinedione derivative; acetylsalicylic acid; angiotensin II antagonist; anticoagulant agent; antidiabetic agent; antihypertensive agent; antilipemic agent; beta adrenergic receptor blocking agent; biguanide derivative; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; diuretic agent; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; nitrate; nonsteroid antiinflammatory agent; sulfonylurea derivative; acute heart infarction; aged; article; atherothrombosis; cardiovascular risk; carotid atherosclerosis; diabetes mellitus; female; health care personnel; hospitalization; human; hypercholesterolemia; hypertension; major clinical study; male; Mexico; mortality; prevalence; stroke; thrombosis; vascular disease; atherosclerosis; Cardiovascular Diseases; clinical trial; middle aged; multicenter study; proportional hazards model; register; risk assessment; risk factor; thrombosis; time; treatment outcome; Aged; Atherosclerosis; Cardiovascular Diseases; Female; Humans; Male; Mexico; Middle Aged; Prevalence; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thrombosis; Time Factors; Treatment Outcome
Identity
Digital Object Identifier (DOI)
PubMed ID
Additional Document Info
start page
end page
volume
issue